Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 32

Abbisko, Lilly Expand Drug Discovery Partnership

Jun 24, 2026
Abbisko Therapeutics has entered into a new strategic research collaboration and license agreement with Eli Lilly and Company to discover and develop innovative medicines across…
Read More...

Boehringer Advances Phase III Cancer Precision Medicine Trials

Jun 23, 2026
Boehringer Ingelheim has announced the launch of three Phase III clinical trials aimed at advancing precision oncology for patients with some of the most aggressive forms of cancer. The…
Read More...

Voro and Alloy Partner on Safer Cancer Immunotherapies

Jun 19, 2026
Voro Therapeutics and Alloy Therapeutics have entered into a strategic research collaboration aimed at developing a new generation of cancer immunotherapies designed to improve the…
Read More...

uniQure Reports Early Promise for Epilepsy Gene Therapy

Jun 19, 2026
uniQure has reported encouraging early clinical results from its experimental gene therapy AMT-260, offering new hope for patients living with refractory mesial temporal lobe epilepsy…
Read More...

Boltz and Takeda Expand AI-Powered Drug Discovery Efforts

Jun 19, 2026
Boltz PBC, an applied artificial intelligence research company focused on biomolecular modeling, has announced a new collaboration with Takeda aimed at bringing advanced AI-driven tools…
Read More...

SK Pharmteco Partners With OTXL for Rare Disease Therapies

Jun 19, 2026
SK pharmteco has entered into a new strategic collaboration with the Orphan Therapeutics Accelerator (OTXL), a non-profit biotechnology organization focused on advancing stalled rare…
Read More...

Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Jun 18, 2026
The success of GLP-1 medicines has changed the way healthcare professionals view obesity and metabolic diseases. Over the past few years, drugs such as semaglutide and tirzepatide have…
Read More...

AI-Designed Drug Candidates Enter Clinical Trials: A New Era for Drug Discovery

Jun 18, 2026
The pharmaceutical industry is entering a new chapter as artificial intelligence (AI) begins to play a larger role in drug discovery and development. What once seemed like a futuristic…
Read More...

Vedana Launches With $46 Million for Migraine Therapies

Jun 18, 2026
Vedana Therapeutics has emerged from stealth mode with $46 million in Series A financing and ambitious plans to develop next-generation therapies for migraine prevention, targeting…
Read More...

LG AI and D&D Pharmatech Join Forces on Oral Peptides

Jun 18, 2026
LG AI Research and D&D Pharmatech have entered into a strategic partnership aimed at accelerating the development of next-generation oral peptide therapies, highlighting the growing…
Read More...
Previous 1 … 30 31 32 33 34 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.